Roche and Molecular Partners AG have entered into a research collaboration and licensing agreement to discover, develop and commercialize several therapeutics using Molecular Partners’ DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer. DARPins are non-antibody-based small proteins that have been engineered for target binding, making them ideal to deliver toxic agents to tumors and kill cancer cells. DARPin-drug conjugates offer the potential of enhanced e...